AstraZeneca Names Onco360 Pharmacy Partner for Zegfrovy
The pharmaceutical company selects the specialty pharmacy to manage nationwide access to the lung cancer medication.
Updated on Oct. 26, 2026 in Cancer
Live Poll
Should pharmaceutical companies be required to expand pharmacy partnerships to increase patient access to cancer drugs?
AstraZeneca has designated Louisville-based Onco360 as a national pharmacy partner to support the distribution of its lung cancer treatment, Zegfrovy. The drug is a kinase inhibitor approved for adults with metastatic non-small cell lung cancer characterized by EGFR exon 20 insertion mutations.
Why it matters
Selecting a national pharmacy partner is a key step for AstraZeneca to ensure patients have access to Zegfrovy as the company launches the medication across the United States. The drug provides a targeted therapeutic option for patients whose disease has progressed following platinum-based chemotherapy.
In the WU-KONG28 phase 3 trial, Zegfrovy achieved an objective response rate of 58.9% compared to 31.1% for platinum-based chemotherapy. Researchers observed a median progression-free survival of 10.3 months with the medication versus 7.5 months in the chemotherapy control group.
The players
AstraZeneca
This global pharmaceutical company specializes in the discovery, development, and commercialization of prescription medicines in areas such as oncology and rare diseases.
Onco360
Headquartered in Louisville, Kentucky, this independent specialty pharmacy provides medication distribution through a network of accredited oncology pharmacies.
The details
Zegfrovy works by binding to the epidermal growth factor receptor to inhibit specific mutations. Patients eligible for the treatment must have progressed on or after standard platinum-based chemotherapy regimens, and the drug is formally included in the NCCN Clinical Practice Guidelines in Oncology.
Timeline
2003: Onco360 was founded.
2025: The Zegfrovy package insert was published.
October 9, 2026: NCCN guidelines were accessed.
October 26, 2026: Onco360 was selected as the Zegfrovy pharmacy partner.
The Big Picture
The drug's inclusion in the NCCN Clinical Practice Guidelines in Oncology provides an evidence-based framework for its clinical adoption. This alignment ensures that Zegfrovy is recognized as a standard therapeutic option within the broader oncology landscape.
Patients with metastatic non-small cell lung cancer can now access Zegfrovy through the specialized pharmacy network managed by Onco360. This distribution model aims to streamline medication delivery for those who have previously undergone platinum-based chemotherapy.
The takeaway
Zegfrovy offers a targeted alternative for patients who have exhausted traditional chemotherapy options. Patients should consult with their oncology care team to determine if their specific genetic mutation makes them a candidate for this kinase inhibitor therapy.
Further reading
For more information on current treatment options, visit the United States Cancer section.
More information
To learn more about their services, visit Onco360 corporate information.
Source note: This article includes information reported by The Manila times.
Live Poll
Should pharmaceutical companies be required to expand pharmacy partnerships to increase patient access to cancer drugs?
